Genmab shares fall as investors reassess DARZALEX royalty outlook and capital actions
Genmab A/S ADS (GMAB) is sliding as investors digest near-term uncertainty around royalties and the company’s post-deal capital structure, despite strong Q1 2026 DARZALEX net sales of $3.964B. The stock is also coming off a share-capital update tied to a treasury-share cancellation completed this week.
1. What’s moving the stock
Genmab’s U.S.-listed ADS are down about 3% in Thursday trading, a move that appears driven by investor repositioning rather than a single fresh headline. The selling comes as the market re-checks the durability of Genmab’s royalty-heavy earnings stream and the company’s financial setup following major recent corporate actions.
2. The fundamental backdrop investors are weighing
The latest concrete operating datapoint is Johnson & Johnson’s reported worldwide net trade sales of DARZALEX (daratumumab) at USD 3,964 million for Q1 2026, with USD 2,208 million in the U.S. and USD 1,756 million outside the U.S. Genmab earns royalties on worldwide DARZALEX net sales, so the sales print supports top-line royalty generation, but investors continue to debate how royalty economics evolve over time and how that affects valuation multiples for a royalty-driven biotech. (ir.genmab.com)
3. Corporate actions adding noise to trading
Separately, Genmab completed a share capital reduction via cancellation of 1.9 million treasury shares, with the share capital expected to be updated in Nasdaq’s system on April 21, 2026. While treasury-share cancellations are generally shareholder-friendly, they can coincide with short-term mechanical trading effects as market data, share counts, and models refresh. (globenewswire.com)